Literature DB >> 31405716

Reverse total shoulder arthroplasty provides stability and better function than hemiarthroplasty following resection of proximal humerus tumors.

Timothy W Grosel1, Darren R Plummer1, Joshua S Everhart1, James C Kirven1, Chance L Ziegler1, Joel L Mayerson1, Thomas J Scharschmidt1, Jonathan D Barlow2.   

Abstract

BACKGROUND: Tumors may necessitate resection of a substantial portion of the proximal humerus and surrounding soft tissues, making reconstruction challenging. We evaluated outcomes in patients undergoing treatment of tumors of the proximal humerus with reverse total shoulder arthroplasty (rTSA) or shoulder hemiarthroplasty.
METHODS: Patients who underwent rTSA (n = 10) or shoulder hemiarthroplasty (n = 37) for tumors of the proximal humerus in 2009 to 2017 were reviewed. Of these patients, 27 had died, leaving 20 for review. The mean follow-up period of the survivors was 27.1 months. They were evaluated clinically and contacted to determine the American Shoulder and Elbow Surgeons score, Simple Shoulder Test score, and visual analog scale score.
RESULTS: Postoperative complications occurred in 13 hemiarthroplasty patients (34%). Tumor recurrence occurred in 3 hemiarthroplasty patients (7.9%), whereas in the rTSA group, 1 patient (10%) had a postoperative complication, with no recurrences. One hemiarthroplasty patient required revision surgery with rTSA to improve shoulder function. Six dislocations and two subluxations occurred in the hemiarthroplasty group, whereas no subluxations occurred in the rTSA group (P = .14). Mean range of motion was 85° of forward flexion for rTSA patients (n = 10) compared with 28° for hemiarthroplasty patients (P < .001). The mean American Shoulder and Elbow Surgeons score was 63 for hemiarthroplasty patients (n = 5) and 59 for rTSA patients (n = 4). The mean Simple Shoulder Test scores were 3.8 and 2.4, respectively. The mean visual analog scale pain scores were 2.4 and 2.5, respectively.
CONCLUSION: Reverse total shoulder arthroplasty can reproducibly reconstruct the shoulder in patients requiring oncologic proximal humerus resection. Patients have good outcomes, better range of motion, and no increase in instability rates compared with hemiarthroplasty.
Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Reverse total shoulder arthroplasty; complications; hemiarthroplasty; proximal humerus; tumors

Mesh:

Year:  2019        PMID: 31405716     DOI: 10.1016/j.jse.2019.02.032

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  4 in total

1.  The Use of Tumor Prostheses for Primary or Revision Reverse Total Shoulder Arthroplasty With Proximal Humeral Bone Loss.

Authors:  Sunita Rp Mengers; Derrick M Knapik; John Strony; Grant Nelson; Evan Faxon; Nellie Renko; Patrick Getty; Robert Gillespie
Journal:  J Shoulder Elb Arthroplast       Date:  2022-01-15

Review 2.  Anatomical and reverse megaprosthesis in proximal humerus reconstructions after oncologic resections: a systematic review and meta-analysis.

Authors:  Michele Fiore; Andrea Sambri; Claudio Giannini; Riccardo Zucchini; Roberto De Cristofaro; Massimiliano De Paolis
Journal:  Arch Orthop Trauma Surg       Date:  2021-03-15       Impact factor: 2.928

3.  Efficacy and safety of a 3D-printed arthrodesis prosthesis for reconstruction after resection of the proximal humerus: preliminary outcomes with a minimum 2-year follow-up.

Authors:  Haijie Liang; Wei Guo; Yi Yang; Dasen Li; Rongli Yang; Xiaodong Tang; Taiqiang Yan
Journal:  BMC Musculoskelet Disord       Date:  2022-07-04       Impact factor: 2.562

4.  Reverse shoulder megaprosthesis replacement for aggressive aneurysm bone cyst of proximal humerus: Case report and literature review.

Authors:  Manh Nguyen Huu; Dung Trung Tran; Viet Vu Duc; Quyet Tran; Quang Minh Dang; Thanh Duc Tran; Sang Quang Tran Nguyen; Cong Van Tran
Journal:  Ann Med Surg (Lond)       Date:  2022-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.